Nanotechnology For Cervical Cancer Diagnosis Could Replace Invasive Pap Smears
|
By LabMedica International staff writers Posted on 31 Jan 2025 |

Cervical cancer is the fourth most common cancer in women globally, almost always caused by the human papillomavirus (HPV), which spreads through sexual contact. The Pap test (or Pap smear) is used to screen for cervical cancer, but access to regular testing is often limited, which raises concerns, as early detection is critical for effective treatment. Menstrual blood, like urine, contains cells and biomarkers that can be tested to provide valuable health information and signal the need for more specific and selective tests. Now, an innovative technology utilizes nanomaterials in menstrual products to detect HPV and cervical cancer using menstrual blood, potentially eliminating the need for Pap smears.
CELLECT Laboratories (Waterloo, ON, Canada) is pioneering the use of nanotechnology-powered menstrual products to non-invasively collect and preserve DNA for diagnosing HPV, cervical cancer, sexually transmitted diseases (STDs), and other reproductive and gynecological conditions. CELLECT has developed a nanomaterial that can be incorporated into tampons or pads, passively capturing and preserving DNA and cells from menstrual blood. This material can then be tested for HPV, cervical cancer, and other DNA-related conditions, including sexually transmitted infections. The lab processing techniques used by CELLECT mirror those employed in standard HPV tests, enabling the differentiation between high-risk and low-risk HPV strains. CELLECT provides a non-invasive alternative to Pap smears by using menstrual products to collect menstrual blood, thereby eliminating the need for more invasive procedures like swabs or speculums.
For women who do not menstruate, CELLECT is also exploring the use of other vaginal fluids, such as discharges, as an alternative sample. The company’s proprietary technology is designed to work with very small volumes of fluid — as little as 15 mm³ — while still achieving the same diagnostic results. This ensures that the solution is inclusive and adaptable, offering a non-invasive and accurate method for women at various health stages. CELLECT has received attention from healthcare professionals and potential users, who are enthusiastic about the prospect of a non-invasive alternative to Pap smears. The company is well-positioned to bring about significant change, providing an accessible and inclusive screening method for people who menstruate, particularly those overlooked by traditional gynecological care models. With early successes in prototype development, CELLECT is on track to revolutionize healthcare.
Related Links:
CELLECT Laboratories
Latest Technology News
- New qPCR Master Mixes Offer Broad Compatibility for Routine Research
- Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
- Personal PCR Analyzer Aims to Enable At-Home Infectious Disease Testing
- Microfluidic Assay Predicts Treatment Response in Pediatric Leukemia
- AI Models Use Routine Blood Tests and Health Records to Predict Cancer Risk
- Compact PCR Thermal Cycler Launches for Routine Molecular Laboratory Workflows
- New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows
- Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
- Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
- New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
- ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
- Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
- New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
- Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
- Autonomous Robotic System Receives FDA Authorization for Blood Collection
- Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Channels
Clinical Chemistry
view channel
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreFDA Authorization Adds Gabapentin Testing to Roche Mass Spectrometry Solution
Clinical laboratories use mass spectrometry for applications requiring highly sensitive and specific measurement, including steroid hormone measurement, vitamin D testing, and therapeutic drug monitoring.... Read moreMolecular Diagnostics
view channel
Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis
Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more
Epigenetic Blood Test Detects Early Breast Cancer and Predicts Recurrence Risk
Breast cancer screening can reduce mortality, but early detection remains challenging when tumors are small or difficult to identify through imaging. Blood-based liquid biopsies offer a potential complementary... Read more
Target-Amplification-Free CRISPR Platform Demonstrates Molecular Detection in Under 10 Minutes
Molecular testing plays an important role in clinical diagnostics, but conventional workflows often require time-consuming procedures and specialized equipment, limiting their use outside centralized laboratories.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







